Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | SIRT6 | Q8N6T7 | 5/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.53 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1393268 | 0.94 | MAPT (0.74) | MAPTPOLBSMN1; SMN2SIRT6RAB9A | |
| SCHEMBL29649854 | 0.87 | MAPT (0.59) | MAPTPOLBSMN1; SMN2SIRT6RAB9A | |
| SCHEMBL10126772 | 0.87 | MAPT (0.59) | MAPTPOLBSMN1; SMN2SIRT6RAB9A | |
| SCHEMBL29435521 | 0.85 | MAPT (0.97) | MAPTPOLBSMN1; SMN2RAB9ALMNA | |
| SCHEMBL15141576 | 0.85 | MAPT (0.97) | MAPTPOLBSMN1; SMN2RAB9ALMNA | |
| SCHEMBL3539759 | 0.85 | MAPT (0.90) | MAPTPOLBSMN1; SMN2RAB9ALMNA | |
| SCHEMBL13139587 | 0.84 | MAPT (0.51) | MAPTPOLBSMN1; SMN2SIRT6RAB9A | |
| SCHEMBL17108488 | 0.84 | MAPT (0.63) | MAPTPOLBSMN1; SMN2SIRT6RAB9A | |
| SCHEMBL29437410 | 0.84 | MAPT (1.00) | MAPTPOLBSMN1; SMN2RAB9ALMNA | |
| SCHEMBL2722856 | 0.84 | MAPT (1.00) | MAPTPOLBSMN1; SMN2RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 437 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595236-B2 | Pyrimidine-2,4-diamine compound and preparation method and application thereof | ANHUI MEDICAL UNIVERSITY (CN) | 2026-04-07 | — | — | US | disclosed |
| US-12398132-B2 | Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin-2-amine as therapeutic agents | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2025-08-26 | — | — | US | disclosed |
| EP-4596051-A2 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | Pharmacosmos Holding A/s (DK) | 2025-08-06 | — | — | EP | disclosed |
| US-12285431-B2 | Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | PHARMACOSMOS HOLDING A/S (DK) | 2025-04-29 | — | — | US | disclosed |
| EP-2968291-B1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | PHARMACOSMOS HOLDING AS (DK) | 2025-04-16 | — | — | EP | disclosed |
| EP-3752497-B1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-114269742-B | Derivatives of 4- (imidazo [1,2-a ] pyridin-3-yl) -N- (pyridinyl) pyrimidin-2-amine as therapeutic agents | 常州千红生化制药股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240109906-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| CN-112920124-B | Pyrimidine-2, 4-diamine compound, and preparation method and application thereof | 安徽医科大学 | 2024-03-01 | — | — | CN | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-12-10 | — | — | US | disclosed |
| CN-101594871-A | Pyrrolopyrimidine compounds and uses thereof | NOVARTIS AG (CH) | 2009-12-02 | — | — | CN | disclosed |
| WO-2009098144-A1 | NOVEL PYRIDINONES AND PYRIDAZINONES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-13 | — | — | WO | disclosed |
| EP-2029145-A2 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | Novartis Ag (CH) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007140222-A2 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2007-12-06 | — | — | WO | disclosed |
| US-20050176773-A1 | Antiproliferative 2-(heteroaryl)-aminothiazole compounds and pharmaceutical compositions, and method for their use | AGOURON PHARMACEUTICALS, INC. | 2005-08-11 | — | — | US | disclosed |
| US-20050038078-A1 | Antiproliferative 2-(heteroaryl)-aminothiazole compounds and pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2005-02-17 | — | — | US | disclosed |
| WO-2004014904-A1 | ANTIPROLIFERATIVE 2-(HETEROARYL)-AMINOTHIAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109906-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | MAPT 2057/4885POLB 252/4885SMN1; SMN2 1629/4885 |
| US-12285431-B2 | Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | RB1, CDK4, CDK6 | MAPT 3872/4885POLB 139/4885SMN1; SMN2 3155/4885 |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | PRKDC, TK2, PNKP | MAPT 2154/4885POLB 129/4885SMN1; SMN2 2559/4885 |
| US-20050176773-A1 | Antiproliferative 2-(heteroaryl)-aminothiazole compounds and pharmaceutical compositions, and method for their use | CDK2, MKI67, CCNK | MAPT 2032/4885POLB 749/4885SMN1; SMN2 2831/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | MAPT 3895/4885POLB 3344/4885SMN1; SMN2 3277/4885 |
| US-12398132-B2 | Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin-2-amine as therapeutic agents | FLT3, CDK2, CDK4 | MAPT 3940/4885POLB 664/4885SMN1; SMN2 2401/4885 |
| US-20050038078-A1 | Antiproliferative 2-(heteroaryl)-aminothiazole compounds and pharmaceutical compositions, and methods for their use | CDK2, CCNK, MKI67 | MAPT 2107/4885POLB 885/4885SMN1; SMN2 2520/4885 |
| US-12595236-B2 | Pyrimidine-2,4-diamine compound and preparation method and application thereof | CTSZ, CTSV, CASP2 | MAPT 3995/4885POLB 1105/4885SMN1; SMN2 1362/4885 |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | BTK, SYK, LYN | MAPT 3675/4885POLB 2410/4885SMN1; SMN2 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.